Amerge (Naratriptan)
Headache 2002 Jan;42(1):56-7
Naratriptan in the prophylaxis of cluster headache.
Loder E.
Harvard Medical School , Boston, Mass 02114, USA.
A 36-year-old man with cluster headache refractory to trials of
standard prophylactic treatment and only partially responsive to
parenteral sumatriptan and inhaled oxygen was admitted to an inpatient
pain unit. The diagnosis of cluster headache was confirmed by direct
observation of a typical attack. Despite efforts at prophylaxis, the
patient continued to experience three to four severe headaches per day.
Attempts to control his headaches with scheduled parenteral
dihydroergotamine were successful, but headaches recurred when the
medication was tapered, and continuous or intermittent use of
parenteral dihydroergotamine was not felt to be a practical option for
the patient. Naratriptan 2.5 mg twice daily completely abolished his
headaches, which recurred when the medication was discontinued. No
electrocardiographic or laboratory abnormalities were observed during
treatment, and the patient reported no side effects.
Cephalalgia.
2002 Dec;22(10):815-7.
Naratriptan in the preventive treatment of cluster headache.
Mulder LJ, Spierings EL.
Department of Neurology, Ikazia Hospital, Rotterdam, the Netherlands.
We describe the preventive use of naratriptan, mostly as add-on to high-dose verapamil treatment, in nine patients with cluster headache. The addition of the naratriptan further improved the headaches in seven of the nine patients.
PMID: 12485208
DISCLAIMER: The information provided on this web site is for educational and informational purposes only. It should not be used as a substitute for seeking professional care or for the diagnosis and treatment of any medical disorder. O.U.C.H. makes no claims as to the scientific/clinical validity of the information on this site OR to that of the information linked to from this site. All information taken from the internet should be discussed with a medical professional!
